# Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.

Source: https://onco.cc/trials/nct05864014/  
OnCo record `nct05864014` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Hetrombopag in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.

## Summary

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors. is a phase 3 interventional study registered as NCT05864014 by Jiangsu HengRui Medicine Co., Ltd., with 213 participants enrolled, started 2023-04-25 and due to reach its primary completion in 2025-03-03. Interventions recorded: Hetrombopag, Hetrombopag plus Placebo and Placebo.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05864014
- Phase: 3
- Setting: Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Hetrombopag for the Treatment of Chemotherapy-induced Thrombocytopenia in Adults With Solid Tumors.
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 213

## Sources

- ClinicalTrials.gov NCT05864014: https://clinicaltrials.gov/study/NCT05864014

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct05864014.json